Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

673
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
673
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

896
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
896
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype.

The Journal of experimental medicine·2026
Same author

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis.

International journal of dermatology·2026
Same author

Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis: STEPIn mechanistic substudy results.

The Journal of allergy and clinical immunology·2026
Same author

Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA.

Dermatology and therapy·2026
Same author

Revue medicale suisse·2026
Same author

[Pigmentary mosaicism: a literature review].

Revue medicale suisse·2026

Related Experiment Video

Updated: Feb 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

Psoriasis: from Pathogenesis to Targeted Therapies.

Curdin Conrad1, Michel Gilliet2

  • 1Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland. curdin.conrad@chuv.ch.

Clinical Reviews in Allergy & Immunology
|January 20, 2018
PubMed
Summary

Psoriasis management has advanced with targeted biologic therapies like monoclonal antibodies, improving outcomes for moderate to severe cases. Personalized treatment is key due to psoriasis

Keywords:
BiologicalsInflammatory pathwaysPathogenesisPsoriasisPsoriasis comorbiditiesTNFα inhibitorsTreatments

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

948
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Related Experiment Videos

Last Updated: Feb 15, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

948
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Area of Science:

  • Dermatology and Immunology
  • Translational Medicine

Background:

  • Psoriasis management has evolved significantly over the past decade.
  • Targeted therapies, particularly monoclonal antibodies, have emerged due to increased understanding of psoriasis pathogenesis.
  • These therapies target key inflammatory pathways like TNF, IL-23, and IL-17.

Purpose of the Study:

  • To review recent advances in psoriasis management.
  • To provide an update on the current therapeutic arsenal, including efficacy, safety, and special indications.
  • To discuss psoriasis as a systemic disease and its comorbidities, alongside future perspectives.

Main Methods:

  • Review of scientific literature on psoriasis pathogenesis and treatment.
  • Analysis of clinical trial data for monoclonal antibody therapies.
  • Discussion of molecular and genetic studies identifying new inflammatory pathways.

Main Results:

  • Monoclonal antibodies targeting TNF/IL-23/IL-17 pathways are safe and effective for moderate to severe chronic plaque psoriasis.
  • Psoriasis is recognized as a heterogeneous disease with distinct inflammatory pathways in different subtypes (e.g., pustular, erythrodermic).
  • Psoriasis is associated with systemic comorbidities, impacting overall patient management.

Conclusions:

  • Advances in understanding psoriasis pathogenesis have led to highly effective targeted therapies.
  • Personalized disease characterization is crucial for optimizing treatment strategies.
  • Ongoing research and development are addressing unmet needs and shaping future psoriasis care.